Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is well-positioned for future success with its globally recognized brands, Hydrafacial and SkinStylus, a strong balance sheet with a cash balance of $206 million, and ongoing innovation and strategic initiatives. Despite recent challenges with execution and competition, management has taken steps to strengthen utilization and broaden growth drivers, while also maintaining a highly recurring revenue model driven by consumable sales. Risks to the company include competitive pressures, consumer demand fluctuations, and the ability to maintain brand recognition and loyalty.

Bears say

SkinHealth Systems is facing several challenges that are negatively impacting its stock's outlook. This includes declining revenue, driven by weak demand for its delivery systems and lower utilization of its consumables in key markets such as the Americas and EMEA. Additionally, management's focus on reducing costs and improving sales is taking longer than expected to show results, and there are concerns about the sustainability of the company's revenue growth. These uncertainties, along with the potential impact of regulatory risks, make it challenging to predict a sustained return to growth and justify a positive outlook on SkinHealth Systems' stock at this time.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.